Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycolic and Salicylic Acid Peel vs Glycolic Acid Peel for Melasma
NCT02812719Phase 1Withdrawn
- Sponsor
- Boston Medical Center
- Start
- Jul 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
01
Overview
Phase 1, randomised trial of Salvax in melasma (2 arms), sponsored by Boston Medical Center. Primary endpoint: Change in pigmentation at 18 weeks. Planned start Jul 2018; status: withdrawn.
02
Drugs
Salvax
03
Conditions
melasma
Beyond the preview
Go deeper on NCT02812719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812719.